2022 "Integration of Development and Application Summit Forum" was grandly held

Recently, the "Integration and Development, Creation of the Future -Integration Development and Application and Application Summit Forum", which is hosted by the Science Popularization Professional Committee of the China Anti -Cancer Association and is exclusively supported by China Resources Biomedicine The pattern is grandly held. As of press time, more than 200,000 people have been watched. Professor Wang Jianxiang, deputy dean of the Hematology Hospital of the Chinese Academy of Medical Sciences, Professor Zhang Qingyuan, deputy dean of the Harbin Medical University, and Assistant Xing Ligang of Shandong Cancer Hospital, deputy dean of Harbin Medical University, as the chairman of this forum Essence At the same time, we will invite many domestic oncology authorized experts to exchange and discuss the standardized management awareness of hematological toxicity involved in the treatment of different treatments of tumors, and strengthening the disposal of drug -related adverse events and response capabilities.

Forum chairman

At the beginning of the forum, Professor Wang Jianxiang opened his resignation to the forum as a representative of an expert. Professor Wang said: "In the process of anti -tumor treatment, hematological and toxicity may occur. Therefore, while scientific treatment of tumors, standardized management and the occurrence of toxic incidents of hematological systems are important effects on improving anti -tumor treatment. Measures. Through this exchanges, we hope that the awareness of standardized management of hematological toxicity caused by tumor treatment can be improved and the treatment and response capabilities of drug -related adverse events can be strengthened. "

Jinan venue: anti -tumor treatment of hematological toxicity urgently requires standardized management

Professor Huang Wei Huang Wei of Shandong Cancer Hospital conducted the theme exchanges of "Standardized Management of Anti -Tumor treatment of hematological toxicity". Professor Huang mentioned that while different anti -tumor treatment methods, while the efficacy of the treatment of anti -tumor, often caused by multiple mechanisms Including neutral granulocytes, anemia, and thrombocytopenia. Hematologist reactions bring many serious hazards such as infection, bleeding risk, and risk of mortality in tumor patients, and may cause patients to adjust or even interrupt the treatment, which is very serious. For platelet reductions requires full management, the main intervention measures include treatment and secondary prevention. Among them, the treatment methods such as the reorganized person Bai Jiekin-11 (RHIL-11) can significantly improve platelet reduction, reduce bleeding risk, and reduce infusion, especially Rhil- 11 (Ⅰ) There is a significant advantage of reducing the duration of platelet decline, faster platelet recovery, and lasting role. It can be considered.

Professor Jie Linna, Professor Huang Wei, and Professor Sun Liqiu from Mudanjiang Cancer Hospital mentioned from the perspective of radiotherapy, oncology, and hematologists. Reducing prevention and treatment should also attract attention. Choosing appropriate drugs is a very important part of prevention and treatment of platelet reduction.

The chairman of the conference Professor Xing Ligang believes that in the clinical treatment process of tumor -related platelets to reduce patients, the widespread application of related drugs can make patients' platelets decrease quickly and lasting. It is hoped that related drugs can better escort the patients in the future.

Tianjin venue: RHIL-11 related heart events are low, preventable and controllable

Professor Chen Yuqing of Henan Provincial People's Hospital mentioned in the theme exchanges of "Rhil-11 Related Heart Event" that RHIL-11 as the preferred medicine for the first-line medication of platelet reduction (CIT) as a tumor chemotherapy, although it is on the cardiovascular vessels, although it is on the cardiovascular vascular blood vessels There are fewer research on adverse reactions in the system, but the existing research shows that the incidence of heart toxicity caused by Rhil-11 is very low, and most of them are mild. The main mechanism is that water sodium is left, which will not directly cause atrial fibrillation.

Overall, RHIL-11 related heart toxicity is anti-controllable and reversible. By restricting sodium salt intake, evaluate risk benefits of patients with a history of heart disease, monitor and take corresponding measures for patients who are easy to induce heart toxic drugs and use high vomiting risk chemotherapy drugs to stop drugs and give symptomatic treatment drugs through drug discontinuation and symptomatic treatment drugs. It can control and reverse the symptoms of cardiac toxicity, and will not affect the continuous treatment of anti -tumor.

During the discussion, Professor Li Jingyi from Tianjin First Central Hospital, Professor Tao Ji of Harbin Medical University, Professor of Qingdao Haici Medical Group, and Professor Chen Yuqing of Henan Provincial People's Hospital said The severity of the RHIL-11 related heart adverse incidents is generally level 1 to 2. Treatment of symptomatic treatment can be used to control and improve related symptoms quickly, and no subsequent anti-tumor treatment occurs.

Harbin venue: Rhil-11 helps reduce blood transfusion dependencies

Professor Wang Jingxuan from Harbin Medical University Affiliated Cancer Hospital conducted the theme exchanges of "New Anti -Tumor Related Anti -Platelets". Platelet reduction is also common in the treatment of new anti -tumors and different mechanisms are different from chemotherapy. There should also be corresponding systematic management. Therefore, the guide/consensus also changes. Plateau growth factor drugs can reduce blood transfusion dependence, so obtaining high guidelines is high Grade recommendation, including RHIL-11 and its new generation of derivatives Rhil-11 (Ⅰ), reorganized human platelets (RHTPO).

In the discussion, Professor Chen Xiangming from Tai'an Central Hospital and Professor Yan Zhenyu from the North China University of Technology Affiliated Hospital mentioned that with the advent of the era of targeted and immune therapy, the application of new anti -tumor treatment methods and the application of joint treatment is becoming more mature and mature and mature and mature and mature and mature and mature and mature and mature and mature and mature and mature. Wide, new anti -tumor treatment is especially in the combined chemotherapy process of immunotherapy. The incidence of hematological toxicity such as platelet reduction has increased, and the severity is also different. In the era of targeted and immunotherapy, the basic diseases of patients should be paid to the patient's basic diseases, a reasonable prevention, effective monitoring, and intervention in a timely manner. Once the platelets are found, active treatment should be performed, including Rhil-11 and its new generation of derivatives Rhil-11 11 (I), reorganized human platelets (RHTPO), etc. (RHTPO), etc. Professor Zhang Qingyuan, chairman of the conference, conducted reviews and summary: Tumor therapy has become more and more accurate after the era of targeted and immunotherapy, but adverse reactions cannot be ignored, such as PD-1/PD-L1, CDK4/6 inhibitors and other drugs. The incidence of platelet reduction in adverse events is high. Therefore, it is necessary to strictly manage the whole process of multi -level prevention and treatment. To prevent patients from serious consequences due to severe platelets outside the hospital, they must not be taken lightly.

Mr. Huang Linchuan, China Resources Biomedicine attended the forum and delivered a speech stating that he hopes to contribute to the long -term development of anti -tumor treatment and platelet enhancement.

This is a professional and practical science popularization event. Under the perspective of multiple perspectives, authoritative experts in the tumor field expresses their own opinions, explore the standardized management of tumor treatment related toxic toxicity, and sharing the diagnosis and treatment model of integrated oncology to solve the problem of concern of primary medical staff care personnel. It aims to strengthen the science popularization of integrated oncology, promote the application of integrated oncology, and protect the patients with tumor patients.

- END -